Results 21 to 30 of about 19,293 (297)

BEV-IP : perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis [PDF]

, 2015
Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC).
Ceelen, Wim, Liberale, Gabriel, Van Der Speeten, Kurt, Willaert, Wouter   +3 more
core   +4 more sources

The Role of Prophylactic and Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Prevention of Peritoneal Metastases in Advanced Colorectal Cancer

Journal of Clinical Medicine, 2023
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a locoregional therapy that may be combined with cytoreductive surgery (CRS) to treat patients with colorectal cancer and peritoneal metastases (PM). In recent years, three randomized controlled trials
Beatrice J. Sun, Sara K. Daniel, Byrne Lee   +2 more
semanticscholar   +1 more source

GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases

BMC Cancer, 2022
Background The French PRODIGE 7 trial, published on January 2021, has raised doubts about the specific survival benefit provided by HIPEC with oxaliplatin 460 mg/m 2 (30 minutes) for the treatment of peritoneal metastases from colorectal cancer. However,
Fernando Magno Quintão Pereira, Á. Serrano, I. Manzanedo, E. Pérez-Viejo, S. González-Moreno, L. González-Bayón, Á. Arjona-Sánchez, J. Torres, I. Ramos, M. E. Barrios, P. Cascales, R. Morales, E. Boldo, A. García-Fadrique, X. Arteaga, A. Gutiérrez-Calvo, S. Sánchez-García, E. Asensio, Cesar P. Ramírez, M. Artiles, J. Vaqué, P. A. Parra, P. Villarejo, Cristóbal Muñoz-Casares, E. Turienzo, A. Calero, I. J. Torrejimeno, I. Prieto, J. Galindo, Vicente Borrego, Manuel E. Marcello, C. Rihuete, J. Carrasco, L. Gómez-Quiles   +33 more
semanticscholar   +1 more source

Therapeutic Value of Hyperthermic Intraperitoneal Chemotherapy on Non-radical Appendiceal Low-grade Pseudomyxoma Peritonei

Zhongliu Fangzhi Yanjiu, 2020
Objective To explore the application value of hyperthermic intraperitoneal chemotherapy(HIPEC) on non-radical appendiceal low-grade pseudomyxoma peritonei(PMP).
SHI Guanjun, XIA Ao, AN Lubiao, ZHAI Xichao, MA Ruiqing, LU Yiyan, PANG Shaojun, CAI Ying, WANG Bing, CHEN Feng, XU Hongbin   +10 more
doaj   +1 more source

The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma

, 2021
Pseudomyxoma Peritonei (PMP) and Peritoneal Mesothelioma (PM) are both rare peritoneal malignancies. Currently, affected patients may be treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy offering long-term survival or even ...
de Hingh, I.,, Deraco, M.,, Glehen, O.,, Govaerts, K.,, Kepenekian, V.,, Kusamura, S.,, Lund University., Lurvink, R.J,, Moran, B.,, PSOGI, Syk, Ingvar,, Van der Speeten, K.,, Villeneuve, L.,   +12 more
core   +1 more source

Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease

Journal of Surgical Oncology, 2022
Gastric cancer (GC) is an aggressive malignancy with a high burden of peritoneal disease. Evidence regarding the use of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to improve outcomes has been growing. However, given
H. Khan, F. Johnston
semanticscholar   +1 more source

Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial

International Journal of Cancer, 2022
The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin to interval cytoreductive surgery improves recurrence‐free (RFS) and overall survival (OS) in patients with stage III ovarian cancer. Homologous recombination deficient (HRD)
S. Koole, P. Schouten, J. Hauke, R. J. Kluin, P. Nederlof, Lisa Richters, Gabriele Krebsbach, K. Sikorska, M. Alkemade, M. Opdam, J. H. Schagen van Leeuwen, H. Schreuder, R. Hermans, I. D. de Hingh, C. Mom, H. Arts, M. van Ham, P. V. van Dam, P. Vuylsteke, J. Sanders, H. Horlings, K. K. van de Vijver, E. Hahnen, W. V. van Driel, R. Schmutzler, G. Sonke, S. Linn   +26 more
semanticscholar   +1 more source

Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model [PDF]

, 2015
Cytoreductive surgery combined with intraperitoneal chemotherapy (IPC) is currently the standard treatment for selected patients with peritoneal carcinomatosis of colorectal cancer.
Ceelen, Wim, De Wever, Olivier, Descamps, Benedicte, Gremonprez, Félix, Izmer, Andrei, Vanhaecke, Frank, Vanhove, Christian   +6 more
core   +7 more sources

Hyperthermic intraperitoneal chemotherapy for patients with gastric cancer based on laboratory tests is safe: a single Chinese center analysis

BMC Surgery, 2022
Purpose About 15%—40% of gastric cancer patients have peritoneal metastasis, which leads to poor prognosis. Hyperthermic intraperitoneal chemotherapy (HIPEC) is considered to be an effective treatment for these patients. This study evaluated the efficacy
Yunzi Wu, Xiaohao Zheng, Chunyang Sun, Shenghui Wang, Shikang Ding, Ming Wu, Jing Zhang, Bingzhi Wang, Liyan Xue, Lin Yang, Yantao Tian, Yibin Xie   +11 more
doaj   +1 more source

Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study

Frontiers in Oncology, 2022
To evaluate the additive effects of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval debulking surgery (IDS) in patients with advanced-stage ovarian cancer.
Yong Jae Lee, Ki Eun Seon, Dae Chul Jung, Jung-Yun Lee, Eun Ji Nam, Sang Wun Kim, Sunghoon Kim, Young Tae Kim   +7 more
doaj   +1 more source